Every 10-Q that Crinetics Pharmaceuticals (CRNX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CRNX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CRNX filings page.
Crinetics Pharmaceuticals reported second-quarter 2026 total revenue of $25,118 (in thousands), driven by $24,038 (in thousands) of net product revenue from its first commercial drug, PALSONIFY for acromegaly, and $1,080 (in thousands) of collaboration and license revenue. The quarter’s net loss was $120,855 (in thousands), with research and development expenses of $99,850 (in thousands) and selling, general and administrative expenses of $57,573 (in thousands).
As of June 30, 2026, Crinetics held $55,498 (in thousands) of cash and cash equivalents and $1,150,275 (in thousands) of investment securities, totaling about $1.2 billion in cash, cash equivalents and investment securities, which the company believes is sufficient to fund operations for at least the next 12 months. In January 2026 it raised approximately $380,000 (in thousands) of net proceeds through an underwritten equity offering.
On July 6, 2026, Crinetics entered into a Merger Agreement under which Vertex Pharmaceuticals will acquire Crinetics for $85.00 per share in cash. The deal is expected to close in the third quarter of 2026, subject to shareholder approval, U.S. and foreign antitrust clearances, and other customary conditions. All unvested stock options and RSUs will fully vest at closing and be cashed out if in-the-money, and Crinetics may owe a termination fee of approximately $350.5 million to Vertex if the agreement is terminated under specified circumstances.
Crinetics Pharmaceuticals reported first‑quarter 2026 results that reflect its transition to a commercial-stage company following the U.S. launch of PALSONIFY for acromegaly. Total revenue was $10.7 million, driven by $10.3 million of PALSONIFY net product sales and $0.4 million of collaboration and license revenue.
The company recorded a net loss of $127.8 million as it continued heavy investment in research and development of paltusotine, atumelnant and other endocrine programs, along with commercial and administrative infrastructure. R&D expenses were $100.1 million and selling, general and administrative expenses were $50.8 million.
Crinetics strengthened its balance sheet with a January 2026 underwritten offering of 8.8 million shares, generating approximately $380 million of net proceeds. As of March 31, 2026, cash, cash equivalents and investment securities totaled $1.3 billion, which management believes will fund operations for at least 12 months.
Crinetics Pharmaceuticals (CRNX) reported Q3 2025 results and its first FDA approval. The FDA approved PALSONIFY (paltusotine) on September 25, 2025 for adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. The quarter did not include product sales.
Revenue was $143 thousand, primarily from a Japan license. Operating expenses rose with commercialization and pipeline spend: research and development $90.5 million and selling, general and administrative $52.3 million. Net loss was $130.1 million (basic and diluted loss per share $1.38), compared with a $76.8 million loss a year ago. Other income was $12.5 million, reflecting interest on investments.
Cash, cash equivalents and investment securities totaled $1.09 billion as of September 30, 2025, and management believes this is sufficient for at least 12 months. The company advanced atumelnant in CAH and ADCS and prepared an SST2-targeted NDC (CRN09682) Phase 1/2 start. Shares outstanding were 94,891,840 as of October 28, 2025.